98%
921
2 minutes
20
Purpose Of Review: Three COVID-19 vaccines obtained emergency authorization from the Food and Drug Administration (FDA) and are widely used in the USA. Unfortunately, there is a paucity of evidence on the safety and efficacy of these vaccines in patients with autoimmune inflammatory rheumatic diseases (AIIRD), as these patients were excluded from all phases of vaccine development. Here we reviewed current data on COVID-19 vaccination in patients with AIIRD, with emphasis on systemic lupus erythematosus (SLE), and provided a comprehensive update on the benefits and risks of vaccination.
Recent Findings: Patients with SLE have worse immune responses following SARS-CoV-2 vaccination than healthy controls. The efficacy of the COVID-19 vaccines seems to be further reduced by immunosuppressive medications, such as glucocorticoids (GC), methotrexate (MTX), mycophenolate/mycophenolic acid (MMF), and rituximab (RTX). However, these data do not substantiate that AIIRD patients are at greater risk of disease flares or have a higher incidence of side effects following vaccination. There is no significant safety concern for the use of COVID-19 vaccines in patients with AIIRD. The benefits of vaccination far outweigh the risks in patients with AIIRD, including SLE. More data are needed to determine the necessity of a booster vaccine dose and appropriate adjustment of immunosuppressants around the administration of vaccine.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8586600 | PMC |
http://dx.doi.org/10.1007/s11926-021-01046-2 | DOI Listing |
Mol Biol Rep
September 2025
School of Arts and Sciences, Department of Natural and Applied Sciences, The American University of Iraq-Baghdad, Baghdad, Iraq.
The COVID-19 pandemic, caused by the continuously evolving SARS-CoV-2 virus, has presented persistent global health challenges. As novel variants emerge, many with enhanced transmissibility and immune evasion capabilities, concerns have intensified regarding the efficacy of existing vaccines and therapeutics. This review provides a comprehensive overview of the current landscape of COVID-19 vaccination, including the development and performance of monovalent and bivalent boosters, and examines their effectiveness against newly emerging variants of interest (VOIs) and variants under monitoring (VUMs), such as JN.
View Article and Find Full Text PDFJ Healthc Sci Humanit
January 2024
Bioethics Honors Student.
Efforts to reduce the unequal impacts and generations of systemic disadvantage and inequality in healthcare for black and brown communities became amplified and were made more urgent during the COVID-19 pandemic. Moreover, public health surveillance systems have been challenged to address the vulnerabilities that residents within these environments and experiences. This paper describes the methodology used to develop a public health ethics and bioethics surveillance system grounded in empathy and care ethics.
View Article and Find Full Text PDFJ Healthc Sci Humanit
January 2024
Institute of Public Health, College of Pharmacy and Pharmaceutical Sciences, Florida A&M University, Tallahassee, FL, USA.
Introduction: COVID-19 infects minority groups with comorbidities at higher rates than whites. In addition, children are at risk of vaccine hesitancy based on parents' acceptance and due to disparity. About twenty percent of workers would get vaccinated, especially if required by work.
View Article and Find Full Text PDFJ Healthc Sci Humanit
January 2024
University of Texas Health, Austin Pediatric Neurosciences at Dell Children's Hospital, 512-628-1855.
The study investigates the potential impact of COVID-19 vaccines on menstrual cycles, with a particular focus on Black women and those with underlying reproductive health conditions. Despite numerous reports of menstrual irregularities post-vaccination, research on this subject remains limited. The study aims to explore whether these irregular cycles could indicate broader reproductive health concerns, such as reduced ovarian reserve, and whether certain vaccines are more likely to cause these changes.
View Article and Find Full Text PDFEur J Public Health
September 2025
Real World Evidence, The Data Analytics Taskforce, European Medicines Agency, Amsterdam, The Netherlands.
The future European Health Data Space (EHDS), a network for secure cross-border data use, could be beneficial for public health initiatives. The HealthData@EU pilot project evaluated possibilities of secondary data use based on five use cases and established a pilot IT infrastructure. This article reports overarching experiences from two public health use cases and the IT development.
View Article and Find Full Text PDF